Reply to G.-F. Li et al, K. Altundag, and N. SG et al.

Autor: Rugo HS; Hope S. Rugo, MD, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Aditya Bardia, MD, MPH, Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; and Sara M. Tolaney, MD, MPH, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Bardia A; Hope S. Rugo, MD, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Aditya Bardia, MD, MPH, Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; and Sara M. Tolaney, MD, MPH, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Tolaney SM; Hope S. Rugo, MD, Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Aditya Bardia, MD, MPH, Medical Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; and Sara M. Tolaney, MD, MPH, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Mar 10; Vol. 41 (8), pp. 1631-1632. Date of Electronic Publication: 2023 Jan 06.

Reply to K. Altundag.

Autor: Underwood EA; Primary Care Research Unit, Department of Family and Community Medicine, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Suite E349, Toronto, ON, M4N 3M5, Canada., Tierney MC; Primary Care Research Unit, Department of Family and Community Medicine, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Suite E349, Toronto, ON, M4N 3M5, Canada. mary.tierney@sunnybrook.ca.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2018 May; Vol. 169 (1), pp. 205. Date of Electronic Publication: 2018 Feb 06.

Reply to ‘Promotion of neurogenesis by human stem cells in high-risk breast cancer survivals after stem-cell supported high-dose therapy’ by K. Altundag et al. (Ann Oncol 2006; 17: 1465)

Autor: A Scherwath

Publikováno v: Annals of Oncology. 17:1465-1466

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::15cd1474317ebb307a1e16d1979514a6
https://doi.org/10.1093/annonc/mdl051

Reply to 'Letter to the Editor on ‘Vinorelbine, methotrexate and fluorouracil (VMF) as first line therapy in metastatic breast cancer: a randomised phase II trial’', by B. Isik and K. Altundag (Ann Oncol 2004; 15: 175)

Autor: Carl Blomqvist

Publikováno v: Annals of Oncology. 15:175

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::05f6a54439aab64b597894c1535c459b
https://doi.org/10.1093/annonc/mdh024

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.